Bevacizumab for BRCA1/2-Mutated Triple-Negative Breast Cancer

Bevacizumab improved pathologic complete response in TNBC patients with germline mutations.

Prior studies have shown that neoadjuvant bevacizumab improved pathologic complete response (PCR) in patients with human epidermal growth factor receptor 2 (HER2)–negative breast cancer (GeparQuinto and NSABP-B40; NEJM JW Oncol Hematol Mar 2012 and N Engl J Med 2012; 366:310 and 299).

Now, to determine whether germline BRCA1/2-mutation status affects PCR in this setting, investigators assessed patients with triple-negative breast cancer (TNBC) from the GeparQuinto study who received neoadjuvant chemotherapy with epirubicin and cyclophosphamide (EC) followed by docetaxel, with or without bevacizumab from the outset of preoperative chemotherapy until surgery. Of 493 patients with genotype data available, 90 (18.3%) had BRCA1/2 mutations, and a…

Reviewing Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)